1,796 material Form 8-K filings that 1,448 companies we cover made with the SEC in May 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Ares Holdings L.P. and certain Ares Management subsidiaries signed Amendment No. 14 to the company's credit agreement on May 21, 2026. The amendment extends the facility's maturity to May 21, 2031 and raises revolver commitments to $2.5 billion, with an uncommitted accordion feature up to $3.0 billion total. The filing describes this as a change to the borrowing terms, with no new obligation amount beyond the revolver commitments.
Maturity extended to May 21, 2031
Revolver commitments increased to $2.5 billion; uncommitted accordion up to $3.0 billion total facility size
Credit spread adjustment for Term SOFR removed; covenant restrictions and events of default modified
Amendment dated May 21, 2026, with JPMorgan Chase Bank, N.A. as agent
On May 27, 2026, Alamo Group Inc. entered into a Fourth Amended and Restated Credit Agreement with Bank of America, N.A. as administrative agent, allowing borrowings of up to $602,500,000. The company has already borrowed $202,500,000 under a term facility, and up to $400,000,000 is available under a revolving facility, with both expiring May 27, 2031. The agreement adds direct debt obligations that carry interest at variable rates and require the company to meet a maximum net leverage ratio and a minimum fixed charge coverage ratio.
Total availability up to $602,500,000; $202,500,000 already borrowed under the term facility
Up to $400,000,000 available under the revolving facility, with commitment fees of 0.125% to 0.30% on unused amounts
Term facility requires equal quarterly principal payments of $1,265,625; facilities expire May 27, 2031
Interest at Term SOFR or base rate plus a margin of 1.25% to 2.25% for SOFR borrowings, based on net leverage
Amanat Acquisition Corp, a blank check company, completed its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share on May 20, 2026. The $75,000,000 raised was placed in a trust account for public shareholders, and the company has 24 months from the IPO closing to complete a business combination, with no target selected as of the filing.
IPO of 7,500,000 Class A ordinary shares at $10.00 per share closed May 20, 2026, for gross proceeds of $75,000,000
Private placement of 300,000 shares to Amanat Sponsor Holdings LLC at $10.00 per share raised $3,000,000
$75,000,000 held in trust account; underwriters have a 45-day option to buy up to 1,125,000 additional shares
Audited balance sheet as of May 20, 2026 shows cash of $2,224,975; company has 24 months to complete a business combination
On May 26, 2026, Teleflex and certain subsidiaries entered into a new credit agreement that refinances their existing Third Amended and Restated Credit Agreement dated November 4, 2022. The new agreement includes a five-year $1.0 billion revolving credit facility, a $500 million term A-1 loan and a $700 million term A-2 loan, and is secured by substantially all assets. The filing states the company must keep its total net leverage ratio at or below 4.50 to 1.00 and its interest coverage ratio at or above 3.00 to 1.00.
Five-year revolving credit facility of $1.0 billion, plus a $500 million term A-1 loan maturing May 26, 2031 and a $700 million term A-2 loan maturing May 26, 2028.
Loans bear interest at Term SOFR plus 1.125% to 2.00%, or an alternate base rate plus 0.125% to 1.00%, adjusted based on net leverage or corporate family rating.
Covenants require a maximum total net leverage ratio of 4.50 to 1.00 and a minimum interest coverage ratio of 3.00 to 1.00.
Obligations are guaranteed by substantially all material domestic subsidiaries and secured by a lien on substantially all assets.
National HealthCare entered a credit agreement on May 26, 2026, providing a $475.0 million senior unsecured term loan and a $50.0 million revolving credit facility. The company expects to draw the full term loan to help fund its purchase of assets and real property from National Health Investors, with closing currently anticipated on or around July 1, 2026. The filing does not report earnings, so shareholders can weigh the new debt against the acquisition's size and the stated closing conditions.
Term loan of $475.0 million and revolving facility of $50.0 million, both maturing five years after the Funding Date
Proceeds expected to help fund the Transaction with National Health Investors under an April 21, 2026 purchase agreement
Commitments terminate automatically if the Funding Date has not occurred by August 31, 2026
Existing credit agreement with Bank of America to be repaid in full at initial funding; no amounts were outstanding as of March 31, 2026
Artelo Biosciences entered a sales agreement with H.C. Wainwright & Co. allowing it to sell up to $6,530,000 of common stock through an at-the-market program, paying the agent a 3.0% commission on gross sales. Separately, Craft Capital Management filed a FINRA arbitration claim against the company over a right of first refusal tied to a March 2026 private placement. The stock sales could dilute existing shareholders, and the outcome of the arbitration is not addressed in the filing.
Sales agreement dated May 26, 2026 allows sales of up to $6,530,000 of common stock, par value $0.001 per share
Sales agent receives a 3.0% commission on gross sales price; company has no obligation to sell any shares
Craft Capital seeks an $880,000 success fee, warrants valued at $880,000, monthly late fees and attorneys' fees over the March 30, 2026 private placement, which raised gross proceeds of about $11 million
JPMorgan Chase said it will redeem all 200,000 outstanding shares of its 3.65% Fixed-Rate Reset Non-Cumulative Preferred Stock, Series KK, on June 1, 2026, under the optional redemption provisions of the governing documents. The shares are represented by 2,000,000 depositary shares, and holders will receive the redemption price of $10,000 per share ($1,000 per depositary share). June 1, 2026 is also the final dividend payment date for the series, so holders of these depositary shares will receive their last scheduled dividend when the redemption is paid.
200,000 Series KK preferred shares, represented by 2,000,000 depositary shares, will be redeemed on June 1, 2026
Redemption price is $10,000 per preferred share, equivalent to $1,000 per depositary share
June 1, 2026 is the final dividend payment date; the dividend record date is May 4, 2026
Payment is made through Computershare Inc., as Depositary, upon surrender of depositary receipts
Minerva Neurosciences entered a Sales Agreement with Leerink Partners LLC for an at-the-market offering of up to $75.0 million of common stock, with a 3.0% commission on gross proceeds. The company is not obligated to sell any shares, so the program could dilute existing shareholders if used. The filing also says the relapse assessment phase of its Phase 3 C19 trial of roluperidone was extended from 40 weeks to 52 weeks after FDA feedback, with topline results still expected in the second half of 2027.
Up to $75.0 million of common stock may be sold through Leerink Partners LLC, under a prospectus supplement dated May 27, 2026
Agent commission is 3.0% of gross proceeds; the company has no obligation to sell any shares
Relapse assessment phase of the C19 trial extended from 40 weeks to 52 weeks after FDA feedback
Topline efficacy results still expected in the second half of 2027; relapse assessment data in the second half of 2028
On May 27, 2026, Entergy New Orleans, LLC issued and sold $90 million of First Mortgage Bonds in two series to institutional investors in a private placement. The bonds carry fixed rates of 5.91% and 6.65% and are a new debt obligation for the utility subsidiary of Entergy.
$35 million of 5.91% First Mortgage Bonds due June 1, 2036
$55 million of 6.65% First Mortgage Bonds due June 1, 2056
Interest is payable semi-annually on June 1 and December 1, starting December 1, 2026
Bonds were issued under the 1987 Mortgage and Deed of Trust and a Twenty-sixth Supplemental Indenture dated May 1, 2026
NextNav Inc. said it will redeem all outstanding public warrants for $0.01 per warrant in cash on June 26, 2026, at 5 p.m. New York City time. Holders can still exercise the warrants for cash at $11.50 per share of common stock until the redemption date, and any unexercised warrants will be redeemed for $0.01 each. The company said the action simplifies its capital structure, and the filing states that private placement warrants are not subject to the redemption.
Redemption price is $0.01 per public warrant, payable in cash, with a redemption date of June 26, 2026, at 5 p.m. New York City time.
Warrant holders can exercise at $11.50 per share until the redemption date, and the company's notice says exercise is voluntary and must be arranged through a broker.
The company cited a common stock closing price of $23.02 on May 26, 2026, and a last sale price of at least $18.00 for 20 trading days within the 30-day period ending May 21, 2026, as the basis for the redemption right.
Approximately 10 million warrants were outstanding as of May 26, 2026, according to the press release.
American Tower completed a registered public offering of 750.0 million euros of 4.000% senior unsecured notes due September 1, 2033, with net proceeds of about 742.7 million euros (approximately $866.7 million). The company plans to use the proceeds to repay borrowings under its revolving credit facility drawn in euros, repay its 500.0 million euro 1.950% notes due 2026, and for general corporate purposes. The filing is a debt financing that adds new borrowing obligations, with covenants limiting mergers, asset sales and liens.
Principal: 750.0 million euros; 4.000% coupon, payable annually in euros from September 1, 2026
Net proceeds approximately 742.7 million euros (about $866.7 million at 1.00 euro = $1.1669)
Proceeds to repay euro revolver borrowings and 500.0 million euro 1.950% notes due 2026, plus general corporate purposes
Notes callable at any time; make-whole applies before July 1, 2033, with a 101% repurchase price upon a Change of Control and Ratings Decline
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.